Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Beta Bionics, Inc. - Common Stock (NQ:BBNX)

18.65 -0.06 (-0.32%)
Streaming Delayed Price Updated: 11:43 AM EDT, Aug 29, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Beta Bionics, Inc. - Common Stock

Beta Bionics Announces Participation at Upcoming Investor Conferences
From Beta Bionics, Inc.
Via GlobeNewswire
Beyond The Numbers: 6 Analysts Discuss Beta Bionics Stock
 
Via Benzinga
Beta Bionics (BBNX) Q2 Revenue Soars 54%
Via The Motley Fool
Topics Intellectual Property
Beta Bionics BBNX Q2 2025 Earnings Call Transcript
Via The Motley Fool
Topics Earnings
Beta Bionics Inc (NASDAQ:BBNX) Surpasses Q2 2025 Estimates and Raises Full-Year Guidance
Beta Bionics (BBNX) beats Q2 2025 revenue and EPS estimates, raises full-year guidance. Shares surge 5.7% as iLet Bionic Pancreas and new insulin pump drive growth. 
Via Chartmill
Earnings Scheduled For July 29, 2025
 
Via Benzinga
Earnings Scheduled For May 6, 2025
 
Via Benzinga
Beta Bionics Reports Second Quarter 2025 Financial Results and Raises Full Year 2025 Guidance
From Beta Bionics, Inc.
Via GlobeNewswire
Sonnet BioTherapeutics Drops 5% Intraday, Rebounds 14% After Hours Amid Delisting Concerns
Sonnet BioTherapeutics Holdings Inc. (NASDAQ: SONN) fell 5.54% on Thursday to close at $3.92, before rebounding 14.29% in after-hours trading to $4.48, amid concerns of a potential NASDAQ delisting. 
Via Benzinga
12 Health Care Stocks Moving In Thursday's After-Market Session
 
Via Benzinga
Beta Bionics to Announce Second Quarter 2025 Financial Results on July 29, 2025
From Beta Bionics, Inc.
Via GlobeNewswire
Beta Bionics Announces Agreement with Abbott to Integrate the iLet Bionic Pancreas with Abbott’s Future Dual Glucose-Ketone Sensor
From Beta Bionics, Inc.
Via GlobeNewswire
Goldman Sachs Bullish On Dexcom And Insulet As Diabetes Tech Surges
Goldman Sachs forecasts strong growth for diabetes tech, backing Dexcom and Insulet while rating Tandem and Beta Bionics as Neutral. 
Via Benzinga
Beta Bionics Stock Gains After Mixed Analyst Coverage; Wolfe Bullish, Goldman Neutral
Wolfe Research initiated coverage with an ‘Outperform’ rating and a $20 target, while Goldman Sachs started at ‘Neutral’ with a $16 target, citing balanced growth prospects and valuation. 
Via Stocktwits
12 Health Care Stocks Moving In Wednesday's Intraday Session
 
Via Benzinga
Beta Bionics Reports First Quarter 2025 Financial Results and Raises Annual Guidance for Full Year 2025
From Beta Bionics, Inc.
Via GlobeNewswire
Beta Bionics to Present at the Bank of America Securities Health Care Conference
From Beta Bionics, Inc.
Via GlobeNewswire
Beta Bionics to Announce First Quarter 2025 Financial Results on May 6, 2025
From Beta Bionics, Inc.
Via GlobeNewswire
Beta Bionics to Host Investor Event on June 22, 2025
From Beta Bionics, Inc.
Via GlobeNewswire
Beta Bionics Announces Board Appointment of Gerard Michel
From Beta Bionics, Inc.
Via GlobeNewswire
Beta Bionics Announces Fourth Quarter and Full Year 2024 Financial Results and Introduces Annual Guidance for Full Year 2025
From Beta Bionics, Inc.
Via GlobeNewswire
Earnings Scheduled For March 25, 2025
 
Via Benzinga
Beta Bionics to Announce Fourth Quarter and Full Year 2024 Financial Results on March 25, 2025
From Beta Bionics, Inc.
Via GlobeNewswire
This Smithfield Foods Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Monday
 
Via Benzinga
This Palantir Technologies Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Thursday
 
Via Benzinga
Infinity Natural Resources Valued At $1.3 Billion In Market Debut
Shares of Infinity Natural Resources jumped almost 11% in their NYSE debut, valuing the oil and natural gas producer at $1.3 billion. The listing arrived amid a more fossil fuel-friendly White House... 
Via Talk Markets
Topics Energy Stocks / Equities
Beta Bionics Announces Closing of $234.6 Million Initial Public Offering and Full Exercise of Underwriters’ Option to Purchase Additional Shares
From Beta Bionics, Inc.
Via GlobeNewswire
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.